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To the Editor: 32 
B-cell receptor (BCR) signaling pathway inhibitors (including Bruton’s tyrosine kinase [BTK] 33 
inhibitors, and phosphatidylinositol-3 kinase inhibitors [PI3Ki]) have shown clinical efficacy in 34 
non-Hodgkin lymphoma (NHL). However, responses to these agents have been limited in depth 35 
and duration. This may be due to resistance to PI3Kδ and BTK inhibitors as monotherapy.1-5 36 
The emergence of resistant clones may be addressed by combining these 2 classes of drugs. 37 
Furthermore, tolerability of these drug classes has been a concern. Combination therapy using 38 
lower doses of one or more classes of inhibitor may address some limitations.  39 
Tirabrutinib (TIRA, formerly ONO/GS-4059) is a selective, irreversible, small-molecule BTK 40 
inhibitor.6, 7 TIRA has greater target selectivity compared with ibrutinib, which is characterized by 41 
high-affinity inhibition of 10 kinases other than BTK.8 In 2 separate phase 1 studies, TIRA was 42 
evaluated for treatment of patients with follicular lymphoma (FL), non-germinal center B-cell 43 
(non-GCB) diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and 44 
lymphoplasmacytic lymphoma (LPL).7, 9 Response rates were 20%–100% across disease types, 45 
with a favorable safety profile.7, 9 The only cardiovascular adverse events (AEs) were atrial 46 
fibrillation/flutter, which occurred in 5 of the 107 patients in the 2 studies, 4 of whom had this as 47 
a pre-existing medical condition.   48 
We assessed the combination of TIRA with a PI3kδ inhibitor (idelalisib [IDELA]) or a SYK 49 
inhibitor (entospletinib [ENTO]). IDELA is a first-in-class PI3Kδ inhibitor approved for the 50 
treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL), small lymphocytic 51 
lymphoma (SLL), and FL in the US and Europe.10 Response rates were 54% and 58% in FL and 52 
SLL, respectively.10 ENTO (formerly GS-9973) is an investigational selective noncovalent 53 
inhibitor of SYK. In a study of patients with FL, LPL, MCL, and marginal zone lymphoma (MZL), 54 
treatment with ENTO 800 mg twice daily resulted in response rates ranging from 12%–35%, 55 
with manageable toxicity.11  56 
The present study was designed to evaluate the safety of TIRA/IDELA and TIRA/ENTO 57 
combinations and define the maximum tolerated dose (MTD) for each combination and 58 
preliminary efficacy in patients with selected subtypes of NHL and CLL. The results from CLL 59 
patients have been reported elsewhere.12 Herein, we report results in NHL patients.  60 
This was a phase 1b, open-label, multicenter, sequential dose-escalation and -expansion study 61 
in patients with R/R NHL (NCT02457598). Eligible patients had a diagnosis of non-GCB DLBCL, 62 
FL, MCL, or other indolent NHL (MZL, SLL, or LPL) as documented by medical records. 63 
Patients had a history of ≥1 prior therapy (but no prior exposure to BTK or PI3K inhibitors), were 64 
not transplant eligible, and had either progressive disease (PD) or no response (stable disease) 65 
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on their most recent treatment regimen. Except for those with LPL, patients had radiologically 66 
measurable presence of ≥1 lymph nodes.  67 
Patients were treated with TIRA ranging from 20 mg to 160 mg QD in combination with IDELA 68 
(50 mg BID or 100 mg QD) or ENTO (200 mg QD or 400 mg QD) according to a standard 3+3 69 
dose-escalation schema (Supplemental Table 1).  70 
The primary endpoint was safety, evaluated by the occurrence of AEs and laboratory 71 
abnormalities defined as dose-limiting toxicities (Supplemental Table 2). Preliminary efficacy 72 
was evaluated by overall response rate (ORR). Secondary endpoints included pharmacokinetic 73 
(PK) parameters, progression-free survival (PFS), duration of response, time to response, and 74 
proportion of patients achieving both complete response (CR) and undetectable minimal 75 
residual disease (MRD). Patients had CT or MRI scans every 12 weeks; those with DLBCL had 76 
an additional scan at week 6. Further details on study methods are provided in the 77 
Supplemental Methods. 78 
Overall, 40 patients were treated with TIRA/IDELA and 91 with TIRA/ENTO (Supplemental 79 
Figure 1). Patient characteristics and baseline demographics of the NHL subtypes included in 80 
this study are shown in Table 1. Forty-seven percent of DLBCL patients in the TIRA/IDELA 81 
group were refractory to their last prior regimen; 67% were refractory to prior regimens in the 82 
TIRA/ENTO group. In the TIRA/IDELA group, 70% of FL patients had failed ≥2 prior therapies, 83 
and 50% had failed both rituximab/anti-CD20+ and alkylating regimens. Eighty percent were 84 
refractory to their last prior treatment regimen before enrolling in this study, with stable or PD as 85 
the best prior response. In the TIRA/ENTO group, most patients were relapsed rather than 86 
refractory, with 65% of FL patients having achieved a response (27% CR, 38% PR) on their last 87 
prior therapy.  88 
Study drug exposures are shown in Supplemental Figure 2 and Supplemental Table 3. In the 89 
TIRA/IDELA and TIRA/ENTO groups, discontinuations due to AEs occurred in 10% and 3% of 90 
patients, and discontinuations due to PD occurred in 60% and 48% of patients, respectively. 91 
Five patients on TIRA/IDELA and 6 patients on TIRA/ENTO died on-study, all due to PD.  92 
In the TIRA/IDELA treatment group, treatment-emergent AEs (TEAEs) occurred in 100% of 93 
patients, with 38% having serious TEAEs (Table 2). TEAEs leading to investigator-determined 94 
TIRA discontinuation occurred in 15% of TIRA/IDELA patients. These included anemia, 95 
neutropenia, pancytopenia, atrial fibrillation, and transaminase increased (1 patient each), and 96 
rash (n=2). TEAEs leading to discontinuation of IDELA occurred in 18% of patients. Grade ≥3 97 
laboratory abnormalities occurred in 69% of TIRA/IDELA patients. The most common 98 
hematologic and hepatic abnormalities (excluding lymphopenia) were decreased neutrophils 99 
and platelets, and increased liver enzymes (Supplemental Table 4). One MZL patient receiving 100 
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TIRA 20 mg BID + IDELA 50 mg BID experienced a dose-limiting toxicity (grade 4 neutropenia 101 
and grade 4 thrombocytopenia), and subsequently the protocol was amended to include only 102 
TIRA QD dosing. MTD with TIRA QD dosing in combination with IDELA was not reached.  103 
In the TIRA/ENTO treatment group, TEAEs occurred in 95% of patients, with 36% having 104 
serious TEAEs (Table 2). TEAEs leading to investigator-determined TIRA discontinuation 105 
occurred in 3% of TIRA/ENTO patients. These included biphasic mesothelioma, lung neoplasm 106 
(malignant), and pancreatitis (1 patient each). TEAEs leading to discontinuation of ENTO 107 
occurred in 8% of patients. Grade ≥3 laboratory abnormalities occurred in 57% of TIRA/ENTO 108 
patients. The most common hematologic and hepatic abnormalities (excluding lymphopenia) 109 
were decreased neutrophils and platelets, and increased liver enzymes (Supplemental Table 110 
4). There were no dose-limiting toxicities in the TIRA/ENTO group and MTD was not reached. 111 
Efficacy results are reported across all dose groups in both combinations. Response rates are 112 
shown in Supplemental Table 5. In DLBCL patients, response rates were comparable across 113 
both combinations; the ORR was 24% with TIRA/IDELA and 26% with TIRA/ENTO. The ORR in 114 
patients with FL was 20% with TIRA/IDELA and 35% with TIRA/ENTO, and in patients with 115 
MCL, ORR was 100% with TIRA/IDELA and 64% with TIRA/ENTO. In patients with other 116 
indolent NHL, the ORR was 58% with TIRA/IDELA and 67% with TIRA/ENTO. The median (Q1, 117 
Q3) time to response and the median (Q1, Q3) duration of response with TIRA/IDELA and 118 
TIRA/ENTO for DLBCL, FL, MCL, and other indolent NHL are shown in Supplemental Table 5; 119 
Kaplan-Meier estimated duration of response is shown separately for each NHL subgroup in 120 
Supplemental Table 6. A ≥50% sum of the products of the longest perpendicular diameters 121 
(SPD) reduction from baseline occurred in 29% and 26% of DLBCL patients, in 20% and 35% of 122 
FL patients, and in 38% and 42% of patients with other NHL subtypes (including MCL) on 123 
TIRA/IDELA and TIRA/ENTO, respectively (Supplemental Figure 3). PFS is shown in 124 
Supplemental Figure 4 and MRD status in Supplemental Figure 5. 125 
The primary objective of this phase 1 study was to assess the safety and tolerability of the 126 
TIRA/IDELA and TIRA/ENTO combinations. The AE rates were generally comparable to those 127 
observed in previous studies of TIRA,7, 9 IDELA,13 or ENTO14 monotherapy in patients with NHL. 128 
There were no unanticipated safety signals seen with either treatment combination at all doses, 129 
and the MTD for either combination was not reached. IDELA-associated toxicities appeared to 130 
be less frequent in our study compared to what has been reported previously, possibly due to 131 
the use of lower doses.10 In particular, no patients receiving TIRA/IDELA had serious TEAEs of 132 
diarrhea, colitis, or ALT/AST elevation.  133 
The combination of TIRA + low-dose IDELA induced responses in only 20% of FL patients, and 134 
the combination of TIRA + ENTO yielded a 35% response rate. These ORRs are lower than 135 
those observed in other studies of R/R FL, including treatment with the approved dose of 150 136 
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mg twice daily IDELA (54% ORR),2, 10 copanlisib (40%-55% ORR),3, 15 and duvelisib (42% 137 
ORR).4 The suboptimal responses in the present study may be due to lower IDELA dosing. 138 
Except in the DLBCL cohort, where the 160 mg TIRA QD dose increased IDELA plasma PK 139 
exposure relative to lower TIRA doses due to drug-drug interaction, no further impact of TIRA 140 
on IDELA PK at lower doses, or additional drug-drug interactions were observed in the study.12 141 
Consistent with a previous IDELA dose-ranging study,13 outcomes in DLBCL patients treated 142 
with TIRA/IDELA (N=17) suggest that reduced IDELA exposure had a detrimental impact on 143 
efficacy.  144 
The overall hypothesis for this study was to explore whether combining different BCR-targeted 145 
agents at lower doses than their respective doses in monotherapy offers a meaningful strategy 146 
to increase tolerability while preserving or improving efficacy. Based on the results of this study, 147 
we conclude that while the explored combinations of TIRA/IDELA and TIRA/ENTO were overall 148 
well tolerated, there was no meaningful efficacy advantage to be gained with this approach. It is 149 
possible that any advantage achieved in safety through lower doses may in fact have 150 
compromised efficacy in this study.   151 
  152 
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TIRA/IDELA, N 17 10 1 12 
Age, median (range) years 72 (37-89) 58 (32-70) 70 (70-70) 68 (41-77) 
Female, n (%) 5 (29) 4 (40) 0 5 (42) 
Time since diagnosis, median (range) years 1.5 (0.3-7.4) 9.3 (0.3-23.0) 3.3 (3.3-3.3) 6.0 (0.0-9.4) 
Ann Arbor staging, n (%)* 
   I-II 
   III or IV 

















Follicular lymphoma staging, n (%) 
   Grade 1 
   Grade 2 
   Grade 3a 





















ECOG performance status, n (%) 
   0 
   1 

















Lactate dehydrogenase, U/L, median 
(range) 
256 (157-924) 256 (176-970) 237 (237-237) 207 (72-411) 
Prior no. of anticancer therapies,  
median (range) 
3.0 (1-4) 4.0 (2-6) 2.0 (2-2) 2.5 (2-5) 
Best response to last regimen, n (%) 
   Complete response 
   Partial response 
   Stable disease 
   Progressive disease 
   Unknown 





























TIRA/ENTO, N 39 26 11 15 
Age, median (range) years 69 (30-89) 67 (37-78) 70 (61-90) 68 (58-85) 
Female 12 (31) 12 (46) 0 3 ( 20) 
Time since diagnosis, median (range) years 1.7 (0.4-23.7) 6.1 (0.3-37.7) 4.6 (1.5-17.1) 6.1 (1.0-19.1) 
Ann Arbor Staging, n (%)† 
   I-II 
   III or IV 

















Follicular lymphoma staging, n (%) 
   Grade 1 
   Grade 2 
   Grade 3a 





















ECOG performance status, n (%) 
   0 
   1 




















Lactate dehydrogenase, median (range) 250 (131-956) 222 (131-492) 208 (146-408) 156 (107-1107) 
Prior no. of anticancer therapies,  
median (range) 
3.0 (1-7) 3.0 (1-12) 3.0 (2-4) 2.0 (1-6) 
Best response to last regimen, n (%) 
   Complete response 
   Partial response 
   Stable disease 
   Progressive disease 
   Unknown 





























*Fifty-five of the 56 DLBCL patients had non-GCB subtype, and 1 patient in the TIRA/IDELA group had GCB subtype (a protocol deviation  
resulting from a delayed pathology report).  
†Follicular lymphoma grading was missing for 4 patients. 
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TEAEs, n (%) 
TEAEs related to TIRA 
TEAEs leading to TIRA discontinuation 
TEAEs related to IDELA 
TEAEs leading to IDELA discontinuation 
TEAEs related to ENTO 















SAEs†, n (%) 
SAEs related to TIRA 
SAEs related to IDELA 









TEAEs by MedDRA preferred term* 
TIRA/IDELA TIRA/ENTO 

















































































MedDRA, Medical Dictionary for Regulatory Activities. 
*TEAEs are shown according to incidence of any grade event occurring in ≥15% of patients in either treatment group. 
†SAEs occurring in ≥2 patients in either treatment group. 
 
 
